CBD – Research Study Publication 2/2
CBD in vapology
In its research study publication on cannabidiol (Understanding CBD and its effects, Mercury M. and Sorin J., 2017), LFEL, brought CBD’s numerous pharmacological properties to light. Anti-inflammatory, a relaxer, anxiolytic, its use can offer significant benefits especially as its toxicological profile is almost non-existent. Frequently associated with the recreational reputation of cannabis, it is also often mistaken for THC which is of psychotropic nature. Although both belong to the cannabinoid family, CBD and THC are, however, two molecules with different profiles. CBD has been studied by the scientific community for many years, which now considers it as a real therapeutic agent, useful in treating specific illnesses, free from side effects and psychotropic effects and which can be administered in various ways.
Concurrently to these developments, vaping products have appeared as a new way of diffusing a molecule which is found in tobacco leaves: nicotine. Over the past several years, the development of these devices has been constantly on the rise. This raises the question: can CBD fit in to this evolution and is it a compound of interest? Likewise, for purposes which are non-medical and nonrecreational, can the personal vaporizer (PV) become an innovative alternative to enjoy the benefits of CBD whilst dissociating it from cannabis which remains controversial? The correlation between the vaping device and CBD’s physical and chemical properties needs to be studied today to assess its potential and to find out whether or not this new use is viable.